Home Magazines Editors-in-Chief FAQs Contact Us

Use of glucocorticoids in covid 19 patients: systematic review

Pharmacy & Pharmacology International Journal
Brigitte Nathalia Tascon Guevara


Introduction: The disease caused by sars-cov-2, covid 19 can generate, in its serious state, acute respiratory distress syndrome (ARDS), patients who must manage in-hospital, respiratory support, and hospitalization in an intermediate and intensive care unit (ICU), The effectiveness and reduction of morbidity and mortality in this group of patients has been demonstrated with the use of glucocorticoids of the dexamethasone type.
Objectives: To describe the action of glucocorticoids in reducing morbidity and mortality in severe covid 19 patients.
Methods: A search was carried out on the use of dexamethasone-type glucocorticoids in covid 19, in the PubMed, Medline and Google Scholar databases.
Results: Covid 19 with a severe course and ARDS can lead to a hyper-inflammatory state, in which the anti-inflammatory properties of steroids can be an effective therapeutic option. Steroid therapy has provento be useful in stabilizing patients hemodynamically, reducing prolonged stays in hospitalization services, intermediate care units, intensive care units, reducing the duration of mechanical ventilation, and reducing morbidity and mortality in this group of patients, serious patients.
Conclusion: Although upto now there is no established therapy that is 100% effective in the treatment of patients with severe covid, it is important to consider dexamethasone as a therapeutic strategy.


dexamethasone, covid19, severe covid19, glucocorticoids, sars-cov-2